GBI Research, the leading business intelligence provider, has released its latest research, Antidepressants Market to 2018 Despite Safety Concerns, Selective Serotonin Re-uptake Inhibitors (SSRIs) Continue to Dominate in the Absence of Effective Therapeutic Alternatives, which provides insights into the antidepressants market until 2018. The report is built using data sourced from our proprietary databases and primary and secondary research, in addition to analysis from our in-house specialized team of experts. The report provides an in-depth analysis of the major antidepressants therapies, including SSRIs, Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs) and Tricyclic Antidepressants (TCAs), covering Major Depressive Disorder (MDD), Obsessive-Compulsive Disorder (OCD), Generalized Anxiety Disorder (GAD) and Panic Disorder (PD).